HUTCHMED has announced that it has completed patient enrolment (64 patients enrolled) for its Phase II registration trial of savolitinib in MET-amplified gastric (stomach) and gastroesophageal junction (GEJ) cancer in China in patients who have received ≥2 lines of standard therapies. Interim results from the trial (presented at the American Association for Cancer Research meeting 2023) have demonstrated encouraging efficacy with savolitinib showing a 45% drug objective response rate (ORR) overa ....
